Rounding Results for Comparison with Specification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rounding Results for Comparison with Specification
The mysteries of rounding are exposed.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 122-124

Three rules for rounding The best explanation of unbiased rounding is in a 1947 textbook written by the statistical research group of Columbia University (2). The senior editor, Churchill Eisenhart from the (then) National Bureau of Standards, was one of the most influential statisticians of his era.

Here are the three rules: Rule 1: If the last digit to be dropped is less than 5, the last digit retained shall be left unchanged.

Rule 2: If the last digit to be dropped is greater than 5, or is 5 followed by digits greater than 0, the last digit retained shall be increased by 1.

Rule 3: If the last digit to be dropped is 5 alone or a 5 followed by 0 only, the last digit retained shall be rounded to the nearest even number.


Figure 1: Decision tree for an unbiased rounding process.
It is usually easier to see how such a rule works if you draw it in a decision tree as shown in Figure 1. In this figure, we designate the digit or figure to be rounded by X, the digit or figure to be dropped by Y, and the difference between the truncated value and the full figure value by Z. Based upon the values of X, Y, and Z, we can arrive at the correct unbiased rounding decision.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here